A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection requiring intravenous treatment.

Trial Profile

A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection requiring intravenous treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Murepavadin (Primary)
  • Indications Bronchiectasis; Pseudomonal infections
  • Focus Therapeutic Use
  • Sponsors Polyphor
  • Most Recent Events

    • 31 Jan 2017 Status changed from completed to discontinued.
    • 27 Jan 2017 This trial has been discontinued in Germany.
    • 25 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top